Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026

Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential ...
quiverquant

Freenome Reports Improved Advanced Precancerous Lesion Detection in Updated SimpleScreen CRC Blood Test

Freenome reports improved sensitivity for detecting advanced precancerous lesions in updated SimpleScreen™ CRC blood test.
Patient Care Online

Updated Freenome CRC Blood Test Detects 18.2% of Advanced Precancerous Lesions

Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood ...
MarketScreener

Freenome, Inc. Presents New Validation Data For Updated Version Of SimpleScreen CRC Blood-Based Screening Test At ACG 2026

Freenome, Inc. announced the company will present late-breaking data on an updated version of its SimpleScreen? CRC blood-based screening test at the American College of Gastroenterology (ACG) 2026 ...
RTTNews

Freenome Highlights Improved SimpleScreen CRC Performance Data At ACG 2026; Stock Up

Freenome, Inc. ( FRNM ), a company that develops blood tests for early cancer detection, announced it will present late-breaking data on an updated version of its SimpleScreen CRC blood-based ...
pharmaphorum

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), its second indication after severe asthma. The anti-TSLP antibody has ...